Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of BAY 73-4506 in previously untreated metastatic or unresectable renal cell carcinoma
2008-000107-28Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in renal cell carcinoma (RCC), sponsored by Bayer. Primary endpoint: Objective response rate. Started Feb 2008; status: completed.
02
Drugs
regorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2008-000107-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000107-28.